Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Results 1-25 of 429 for your search:
Start Over
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: ABI-007-NSCL-005, NCI-2014-02488, NCT02151149
NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study
Phase: Phase IV
Type: Supportive care
Age: 18 and over
Trial IDs: NEO09-100, NCI-2012-02974, NCT01394978
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0301, NCI-2013-00592, 1209-1184, NCT01774578
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CO-1686-022 (TIGER-1), NCI-2014-02300, NCT02186301
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
Comparison of Different Types of Surgery in Treating Patients with Stage IA Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 140503, NCI-2009-00447, CDR0000555324, ECOG-40503, NCT00499330
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LF-0208, NCI-2009-01425, NCT00706862
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 20070782, NCI-2010-00172, NCT00858364
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: AMI-2008-01, NCI-2014-02587, NCT00882609
Immunotherapy With Racotumomab in Advanced Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EC-AR-1E10 MAb-301, NCI-2014-01371, ISRCTN47153584, NCT01460472
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TV1011-LC-303, NCI-2015-00116, 2012-002447-14, NCT01630733
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378A2303, NCI-2014-00520, 2012-005637-36, NCT01828112
Patient Navigation Intervention in Improving Surgery Rates in African Americans with Early Stage Non-small Cell Lung Cancer
Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Age: 21 and over
Trial IDs: 01414, NCI-2014-02559, 101487, WF-01414, WFU-01414, NCT01885455
Comparing Photon Therapy To Proton Therapy To Treat Patients with Lung Cancer
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: RTOG-1308, NCI-2013-01850, NCT01993810
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ABI-007-NSCL-003, NCI-2014-01528, 2014-003804-66, NCT02027428
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: U31287-A-U301, NCI-2014-01446, NCT02134015
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 15296, NCI-2014-02441, 2013-004662-33, I3Y-MC-JPBK, NCT02152631
Start Over